Transgene’s Combined General Meeting of May 15, 2024
May 15 2024 - 10:45AM
Transgene’s Combined General Meeting of May 15, 2024
Strasbourg, France, May 15, 2024,
05:45 p.m. CEST – The Combined Ordinary and
Extraordinary General Meeting of Transgene’s shareholders was held
today (May 15, 2024) at 10:00 a.m. at the Company’s headquarters
(400 boulevard Gonthier d’Andernach – Parc d’Innovation – 67400
Illkirch-Graffenstaden, France).
The meeting was chaired by Alessandro
Riva, Chairman and CEO, to approve the Company’s financial
statements for the year ended December 31, 2023, and to vote on the
other resolutions submitted for approval.
The replay of the Combined General Meeting is
available via Transgene’s website and here.
The Combined General Meeting adopted all
resolutions recommended by the Board of Directors.
The Combined General Meeting notably has
appointed one new director, Michel Baguenault de Puchesse, as
non-independent director.
Michel Baguenault de Puchesse brings to the
Board of Directors his expertise in legal, financial and human
resources matters as well as in corporate organization and
governance. Michel has been CEO of Institut Mérieux since January
2020. Prior to this position, Michel held several positions within
the Institut Mérieux group: Executive Vice President of Institut
Mérieux (2009 – 2011), Corporate Vice President, HR and
Communication of bioMérieux (2011 – 2016), Secretary General of
bioMérieux, in charge of Human Resources, Communication, Audit -
Risks & Compliance, and Protocol (2016 – 2020).
Before joining Institut Mérieux, he was
Financial Strategy Advisor at Financière Meeschaert, from 1996 to
2004, and Head of Development at Banque Martin Maurel in Lyon, from
2004 to 2008.
Michel Baguenault de Puchesse is a graduate from
EM LYON Business School and holds a Law degree.
Within the Institut Mérieux Group, Michel
Baguenault de Puchesse is a board member of Institut Mérieux,
Mérieux NutriSciences, Fondation Christophe & Rodolphe Mérieux,
and non-executive President of Mérieux Equity Partners.
Outside the Group, he is board member of CIC
Lyonnaise de Banque, Descours & Cabaud SA, Mutuelles AXA,
Siparex / Sigefi, Fondation Solidarités by Crédit Agricole. He also
joined the supervisory board of Unibel.
Transgene’s Board of Directors is now
comprised of the following members:
- Dr. Alessandro Riva, Chairman;
- Alain Mérieux, Honorary Chairman;
- Philippe Archinard, Director;
- Michel Baguenault de Puchesse, Director;
- Jean-Luc Bélingard, Director;
- Prof. Jean-Yves Blay, independent Director;
- Sandrine Flory, Director (TSGH representative);
- Benoît Habert, independent Director;
- Marie Landel, independent Director;
- Maya Saïd, independent Director;
- Carol Stuckley, independent Director.
The Board is now composed of 10 members. In
terms of independence and diversity, the Board of Directors is
compliant with the applicable rules, namely: 4 independent
directors out of 10, i.e. 40%, and 4 women out of 10, i.e. a parity
of 40%.
Detailed voting results are available on
Transgene’s website, under the heading Investors > General
Meeting.
***
Contacts
Transgene:Lucie Larguier Chief
Financial
Officer+33 (0)3 88 27 91 04investorrelations@transgene.fr |
Media Transgene:MEDiSTRAVA
Sylvie Berrebi / Frazer Hall+44 (0)203 928
6900transgene@medistrava.com |
About Transgene
Transgene (Euronext: TNG) is a biotechnology
company focused on designing and developing targeted
immunotherapies for the treatment of cancer. Transgene’s programs
utilize viral vector technology with the goal of indirectly or
directly killing cancer cells. The Company’s clinical-stage
programs consist of a portfolio of therapeutic vaccines and
oncolytic viruses: TG4050, the first individualized therapeutic
vaccine based on the myvac® platform, TG4001 for the treatment of
HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic
viruses based on the Invir.IO® viral backbone. With Transgene’s
myvac® platform, therapeutic vaccination enters the field of
precision medicine with a novel immunotherapy that is fully
tailored to each individual. The myvac® approach allows the
generation of a virus-based immunotherapy that encodes
patient-specific mutations identified and selected by Artificial
Intelligence capabilities provided by its partner NEC. With its
proprietary platform Invir.IO®, Transgene is building on its viral
vector engineering expertise to design a new generation of
multifunctional oncolytic viruses.Additional information about
Transgene is available at: www.transgene.frFollow us on social
media: X (formerly Twitter): @TransgeneSA – LinkedIn:
@Transgene
Disclaimer
This press release contains forward-looking
statements, which are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
anticipated. The occurrence of any of these risks could have a
significant negative outcome for the Company’s activities,
perspectives, financial situation, results, regulatory authorities’
agreement with development phases, and development. The Company’s
ability to commercialize its products depends on but is not limited
to the following factors: positive pre-clinical data may not be
predictive of human clinical results, the success of clinical
studies, the ability to obtain financing and/or partnerships for
product manufacturing, development and commercialization, and
marketing approval by government regulatory authorities. For a
discussion of risks and uncertainties which could cause the
Company’s actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque”)
section of the Universal Registration Document, available on the
AMF website (http://www.amf-france.org) or on Transgene’s website
(www.transgene.fr). Forward-looking statements speak only as of the
date on which they are made, and Transgene undertakes no obligation
to update these forward-looking statements, even if new information
becomes available in the future.
- 20240515_Transgene_General_Meeting_2024_EN
Transgene (EU:TNG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Transgene (EU:TNG)
Historical Stock Chart
From Sep 2023 to Sep 2024